GlycoMimetics completed the merger with Crescent Biopharma.

GlycoMimetics, a late clinical-stage biotechnology company, completed the merger withe Crescent Biopharma, a biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. Financial terms were not disclosed. “With our seasoned team, promising pipeline, and solid financial foundation supported by leading biotechnology investors, Crescent is well-positioned to lead the next wave of therapeutic innovation for people living with cancer. We anticipate dosing patients in early 2026 in our global Phase 1 trial for CR-001, a PD-1 x VEGF bispecific antibody. Based on the intentional design of CR-001 to replicate a clinically validated approach, we expect the data we generate in patients with solid tumors to be meaningful. We are also advancing two novel ADCs, starting with our CR-002 program which we anticipate entering the clinic in the middle of next year. Our hope is to rapidly bring new treatment options for cancer patients that could truly make a difference in their lives,” Joshua Brumm, Crescent CEO.